Mural Oncology PLC Logo

Mural Oncology PLC

Clinical-stage biotech developing novel cytokine-based cancer immunotherapies.

MURA | BUD

Overview

Description

Mural Oncology PLC is a clinical-stage biotechnology company that discovers and develops immunotherapies for cancer treatment. The company leverages its proprietary protein engineering platform to create novel, cytokine-based therapies. Its primary focus is on developing first- and best-in-class drugs for difficult-to-treat tumor types where other immunotherapies, such as checkpoint inhibitors, have not been effective. The company's pipeline is led by nemvaleukin alfa, a novel, engineered IL-2 variant immunotherapy. This candidate is being evaluated in clinical trials for various advanced solid tumors, including platinum-resistant ovarian cancer and advanced melanoma, addressing areas of high unmet medical need.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-05 13:45
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion …
English 9.3 KB
2025-12-03 22:30
Mural Oncology Announces Sanction of the Scheme by the High Court
English 12.8 KB
2025-11-26 15:00
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisi…
English 10.1 KB
2025-10-24 22:25
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisiti…
English 31.3 KB
2025-09-24 01:52
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement …
English 18.3 KB

Automate Your Workflow. Get a real-time feed of all Mural Oncology PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mural Oncology PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mural Oncology PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.